愛科百發在第12屆國際呼吸道合胞病毒(RSV)年會上報告了愛司韋™在RSV感染的住院嬰幼兒中的三期臨床試驗(AIRFLO)積極結果
06 oct. 2022 23h39 HE
|
Shanghai Ark Biopharmaceutical Co., Ltd.
中國上海, Oct. 07, 2022 (GLOBE NEWSWIRE) --...
爱科百发在第12届国际呼吸道合胞病毒(RSV)年会上报告了爱司韦™在RSV感染的住院婴幼儿中的三期临床试验(AIRFLO)积极结果
06 oct. 2022 23h39 HE
|
Shanghai Ark Biopharmaceutical Co., Ltd.
中国上海, Oct. 07, 2022 (GLOBE NEWSWIRE) --...
Ark Biopharmaceutical Presents Positive Results in Phase 3 AIRFLO Study of Ziresovir in RSV-Infected Hospitalized Infants at 12th International RSV Symposium
06 oct. 2022 23h39 HE
|
Shanghai Ark Biopharmaceutical Co., Ltd.
SHANGHAI, China, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Results from Shanghai Ark Biopharmaceutical Co., Ltd. (Ark Biopharmaceutical)’s successful Phase 3 study (AIRFLO) with the respiratory syncytial...
Cocrystal Pharma Announces Presentation of Preclinical Characterization Data of CC-42344 at the 6th ISIRV-AVG Conference
13 nov. 2018 11h50 HE
|
Cocrystal Pharma, Inc.
- Company’s novel, broad spectrum influenza antivirals specifically designed to be effective against all significant A strains of the influenza virus - - CC-43244, Company’s lead molecule has...